Fig. 4

DCZ5417 inhibits MAPK signaling pathway. a–d A Gene expression profiling was performed after H929 cells were treated with 10 µmol/L DCZ5417 for 48 h. Representational and pathway analysis of differentially expressed genes in DCZ5417 or DMSO treated cells. a Volcano plot and bar graphs; b GO terms; c KEGG pathways. d Gene Set Enrichment (GSEA) analysis was conducted. An enrichment plot for MAPK pathway in cells. e Immunoblotting analysis of p-ERK/ERK and p-MEK/MEK in cell lysates of H929 and OCI-MY5 cells treated with indicated concentration of DCZ5417. f Relative mRNA expressions of ETS, MYC, ELK and FOS were examined in H929 and OCI-MY5 cells treated with DCZ5417 or DMSO. g Activity of DCZ5417 against H929 and OCI-MY5 cell lines cultured in the presence or absence of IL-6 and IGF-1 for 48 h. Error bars, SD. The result is expressed as means ± SD of three independent experiments. h H929 and OCI-MY5 cells were collected after DCZ5417 treatment with IL-6 or not, and then relative expression of p-ERK/ERK was analyzed by Immunoblotting. All results are expressed as means SD of three independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 versus the control group